The dual treatment significantly enhanced the infiltration and activation of CD8+ T cells in the tumors (Fig. 6j, k and Supplementary Fig. S8k), leading to obvious tumor retardation (Fig. 6h, i). The gene discussed is CD8A; the disease is neoplasm.